Tempus AI, Inc. (NASDAQ:TEM – Get Free Report)’s share price traded up 6.9% on Thursday . The company traded as high as $49.75 and last traded at $50.44. 1,259,494 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 5,533,104 shares. The stock had previously closed at $47.17.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Guggenheim reduced their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price on the stock. TD Cowen lifted their target price on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Morgan Stanley reduced their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $68.64.
Get Our Latest Research Report on TEM
Tempus AI Stock Performance
Tempus AI (NASDAQ:TEM – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.
Insider Activity at Tempus AI
In other Tempus AI news, CFO James William Rogers sold 10,853 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $478,291.71. Following the transaction, the chief financial officer owned 126,395 shares in the company, valued at $5,570,227.65. The trade was a 7.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $181,392.12. Following the transaction, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. This represents a 5.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 392,057 shares of company stock valued at $18,835,714 over the last 90 days. Corporate insiders own 24.26% of the company’s stock.
Institutional Trading of Tempus AI
A number of hedge funds and other institutional investors have recently modified their holdings of TEM. GC Wealth Management RIA LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth about $399,267,000. Vanguard Group Inc. increased its position in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares during the last quarter. Voloridge Investment Management LLC increased its position in shares of Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after acquiring an additional 965,730 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Tempus AI during the second quarter worth about $54,020,000. 24.22% of the stock is owned by hedge funds and other institutional investors.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Articles
- Five stocks we like better than Tempus AI
- Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It
- Is Co-Diagnostics National Security’s Next Diagnostic Pick?
- If the Market Rally Stalls, This ETF Can Insulate Portfolios
- Semtech’s Explosive Rally May Only Be Getting Started
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
